Proteon Therapeutics Raises $19 Million In Venture Capital Funding

KANSAS CITY, Mo.--(BUSINESS WIRE)--March 30, 2006--Proteon Therapeutics, Inc., a biotechnology company developing therapeutics to dilate human veins and arteries for use in vascular surgery and angioplasty, announced today that it has raised $19 million in a Series A venture capital round. TVM Capital and Skyline Ventures co-led the investment, which also included Prism Venture Partners and Intersouth Partners. As a result of the investment, TVM Capital General Partner Stephen J. Hoffman, Ph.D., M.D.; Skyline Ventures Partner David G. Lowe, Ph.D.; and Prism Venture Partners Principal Brendan O'Leary, Ph.D., have joined the Proteon Therapeutics Board of Directors.